DAVID S. GRAYZEL, Director at Surface Oncology, holds 1.80M shares in Aerovate Therapeutics (Ticker: AVTE), holds 0.00 shares in Surface Oncology (Ticker: SURF), holds ― shares in Q32 Bio (Ticker: QTTB). Most recently, DAVID S. GRAYZEL Sold ― shares of Aerovate Therapeutics on Apr 11, 2024 for an estimated value of 334.48K.
What is the percentage of profitable transactions made by DAVID S. GRAYZEL?
The percentage of profitable transactions made by DAVID S. GRAYZEL is 50%.
What is the average return per transaction made by DAVID S. GRAYZEL?
The average return per transaction made by DAVID S. GRAYZEL is 12.10%.
What stocks does DAVID S. GRAYZEL hold?
DAVID S. GRAYZEL holds: SURF, AVTE, QTTB stocks.
What was DAVID S. GRAYZEL’s latest transaction?
DAVID S. GRAYZEL latest transaction was an Informative Sell of $334.48K.
What was DAVID S. GRAYZEL's most profitable transaction?
DAVID S. GRAYZEL’s most profitable transaction was an Informative Sell of AVTE stock on April 11, 2024. The return on the trade was 90.10%.
What is DAVID S. GRAYZEL's role in Surface Oncology?
DAVID S. GRAYZEL's role in Surface Oncology is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.